COMMUNIQUÉS West-GlobeNewswire

Precision Optics Reports First Quarter Fiscal Year 2026 Financial Results
13/11/2025
Conference Call Scheduled for today, November 13, 2025, at 5:00pm ET GARDNER, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced [...]
TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded Warrants
13/11/2025
MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the pricing of [...]
Catheter Precision (VTAK) Reports Third Quarter and First Nine Months 2025 Results of Operations
13/11/2025
Sales Revenue Up 135% over Q3 2024 FORT MILL, S.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on the cardiac [...]
NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations
13/11/2025
Four new patent applications filed that aim to expand the Curadigm Nanoprimer platform intellectual property portfolio and support an initial proprietary internal pipeline of Nanoprimer products in addition to external [...]
NANOBIOTIX annonce les avancées de sa plateforme de nanoprimer Curadigm avec une mise à jour des plans de développement pour son pipeline interne et des collaborations externes
13/11/2025
Quatre nouvelles demandes de brevets déposées visant à étendre la propriété intellectuelle de la plateforme de nanoprimer Curadigm et contribuer au premier pipeline interne et propriétaire de produits associés avec un [...]
Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights
13/11/2025
Presented new data at the Society of Immunotherapy for Cancer (SITC) annual meeting on CLD-401 protection from immune clearance after systemic administration; data also demonstrates that the platform can effectively [...]
Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
13/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated [...]
Sienna Reports Third Quarter 2025 Financial Results and Continues Growth in Greater Toronto Area
13/11/2025
MARKHAM, Ontario, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced its financial results for the three and nine months ended September 30, 2025. [...]
Nyxoah Reports Third Quarter 2025 Financial and Operating Results
13/11/2025
REGULATED INFORMATION Nyxoah Reports Third Quarter 2025 Financial and Operating Results US launch off to a strong start. First commercial Genio implants completed with widespread payer coverage drives initial revenue. [...]
Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Troisième Trimestre 2025
13/11/2025
INFORMATIONS RÉGLEMENTÉES Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Troisième Trimestre 2025 Lancement réussi aux États-Unis. Les premières implantations commerciales de Genio, largement prises [...]
ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates
13/11/2025
Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential best-in-class efficacy and safety Bolstered leadership team with the [...]
Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
13/11/2025
– NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients – – Acute unmet need in R/R NPM1 -mutated AML defined by historically poor outcomes and low survival rates at relapse – – [...]
Legend Senior Living® Expands Presence to New Jersey, Welcoming Azalea of Cinnaminson
13/11/2025
WICHITA, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Legend Senior Living ® , a nationally recognized senior living provider based in Wichita, KS, has announced the management of Azalea of Cinnaminson. This marks the [...]
Inventiva announces trading resumption of its ordinary shares on Euronext Paris
13/11/2025
Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-stage biopharmaceutical company focused on the [...]
Inventiva annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris
13/11/2025
Daix (France), New York City (New York, États-Unis), le 13 novembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de [...]
Zone School of Healing Celebrates Eight-Year Milestone as One of the Fastest-Growing Chiropractic & Healing Schools Worldwide
13/11/2025
FRANKLIN, Tenn., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Zone School of Healing is proudly celebrating over eight years of transformative growth and success, solidifying its position as one of the fastest-growing schools [...]
U.S. Oral Surgery Management Secures New Partner Practices in Three States
13/11/2025
IRVING, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- U.S. Oral Surgery Management ( USOSM ) – a management services organization that exclusively serves premier oral and maxillofacial surgeons – has three new partner [...]
Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares
13/11/2025
Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-stage biopharmaceutical company focused on the [...]
Inventiva annonce les modalités définitives ainsi que l'extension de l'offre au public d'American Depositary Shares d'approximativement 150 millions de dollars
13/11/2025
Daix (France), New York City (New York, États-Unis), le 13 novembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de [...]

Pages